148 related articles for article (PubMed ID: 24550332)
1. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.
Custodio JM; Rhee M; Shen G; Ling KH; Kearney BP; Ramanathan S
Antimicrob Agents Chemother; 2014 May; 58(5):2564-9. PubMed ID: 24550332
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.
Bruce RD; Winkle P; Custodio JM; Wei X; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
Antimicrob Agents Chemother; 2013 Dec; 57(12):6154-7. PubMed ID: 24080665
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM; Gordi T; Zhong L; Ling KH; Ramanathan S
J Clin Pharmacol; 2016 Jun; 56(6):723-32. PubMed ID: 26449283
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.
Ramanathan S; Mathias A; Wei X; Shen G; Koziara J; Cheng A; Kearney BP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):45-50. PubMed ID: 23774876
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
German P; Warren D; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
[TBL] [Abstract][Full Text] [Related]
9. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
10. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
[TBL] [Abstract][Full Text] [Related]
11. Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study.
Yonemura T; Okada N; Sagane K; Okamiya K; Ozaki H; Iida T; Yamada H; Yagura H
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):737-743. PubMed ID: 29364579
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
[TBL] [Abstract][Full Text] [Related]
13. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
[TBL] [Abstract][Full Text] [Related]
14. Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
Midde NM; Rahman MA; Rathi C; Li J; Meibohm B; Li W; Kumar S
PLoS One; 2016; 11(2):e0149225. PubMed ID: 26872388
[TBL] [Abstract][Full Text] [Related]
15. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
[TBL] [Abstract][Full Text] [Related]
16. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Schrijvers R; Debyser Z
Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
[TBL] [Abstract][Full Text] [Related]
18. Elvitegravir for the treatment of HIV.
Unger NR; Worley MV; Kisgen JJ; Sherman EM; Childs-Kean LM
Expert Opin Pharmacother; 2016 Dec; 17(17):2359-2370. PubMed ID: 27767362
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
20. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Majeed SR; West S; Ling KH; Das M; Kearney BP
Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
